Krystal Biotech (NASDAQ:KRYS) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note published on Wednesday,Benzinga reports. The firm currently has a $221.00 price target on the stock.

Other equities analysts have also recently issued reports about the stock. Chardan Capital restated a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Citigroup increased their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $187.86 on Wednesday. The company has a fifty day moving average of $157.37 and a two-hundred day moving average of $175.23. The stock has a market capitalization of $5.40 billion, a PE ratio of 62.83 and a beta of 0.84. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.30 earnings per share. Research analysts forecast that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech in the third quarter valued at approximately $40,000. Values First Advisors Inc. purchased a new position in shares of Krystal Biotech in the third quarter valued at approximately $53,000. Huntington National Bank boosted its stake in shares of Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after purchasing an additional 283 shares during the period. Blue Trust Inc. boosted its stake in shares of Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after purchasing an additional 412 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech in the fourth quarter valued at approximately $95,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).